Abstract: Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.
FORM - 2
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See Section 10 and Rule 13)
COMPOSITION COMPRISING A20LE FUNGICIDE AND WATER SOLUBLE METAL SALT
HINDUSTAN UNILEVER LIMITED, a company incorporated under
the Indian Companies Act, 1913 and having its registered office
at 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India
The following specification particularly describes the invention and the manner in which it is to be performed
COMPOSITION COMPRISING AZOLE FUNGICIDE AND WATER SOLUBLE METAL SALT
The present invention relates to compositions ior treating or preventing hair fail.
Despite the prior art there remains a need for improved compositions for treating or preventing hair fail.
Accordingly, there is provided a hair treatment composition comprising an azole fungicide and zinc gluconate, and wherein the composition does not comprise Trichogen® Veg LS 8960.
Preferably, the azole fungicide is clirnabazole or ketoconazole.
Preferably, the azole is present at from 0.0001 to 1 % wt. of the composition.
Preferably, the zinc gluconate is present at from 0.001 to 2% wt. of the composition. More preferably, the composition comprises from 0.005 to 1% wt. of the composition.
Preferably, the composition does not comprises a synergistic mixture of a healthy scalp protein biosynthesis stimulant, a glycosamino production agent, a cell nutrition regulator, a microcirculation promotor and mixtures thereof.
Preferably the composition does not comprises a synergistic trichogenic mixture of a protein biosynthesis stimulant selected from a sulfopeptide of soy, amino acids, glutamine, glutamic acid, hydrolysed protein extracts, particularly sulfopeptides of soy and amino acids, especially tyrosine, arginine, ornithine and citrulline. Preferably, the composition does not comprise a glycosamino production agent selected from the group consisting of glucosamine, L-fucose; fucose rich polysaccharide, xylose, vitamin C, Eriobotrya japonica extract, N-acetyl
giucosamine, glucosamine sulphate, lysophospholipids, protamine and mixtures thereof. Particularly preferred is glucosamine.
Preferably, the composition does not comprise a ceil nutrition regulator especially vitamins of the B group, carnitine, co-enzyme Q10, creatine, taurine, acetyl-carnitine and mixtures thereof. Particularly preferred are vitamins of the B group, especially PP, B5 and biotin,
Preferably, the composition does not comprise a microcirculation promoter, more preferably a microcirculation promoter selected from Panax Ginseng Extract, Arctium Majus Extract, nitric oxide, niacin, caffeine, gingko biloba extract, bicyclic monoterpene diols, a-lipoic acid, ximenynic acid, proanthocyanidins, arginine and mixtures thereof.
Preferably, the composition does not comprise a protein biosynthesis stimulant selected from a suJfopeptide of soy, amino acids, glutamine, glutamic acid, hydrolysed protein extracts.
Preferably, the composition does not comprise a glycosamino production agent selected from giucosamine, L-fucose; fucose rich polysaccharide xylose.vitamin C, Eriobotrya Japonica extract, N-acety! glucosamine, glucosamine sulphate, lysophospholipids, protamine and mixtures thereof.
Preferably, the composition does not comprise a cell nutrition regulator is selected from vitamins of the B group, carnitine, co-enzyme Q10, creatine, taurine, acetyf-carnitine and mixtures thereof.
Preferably, the composition does not comprise a microcirculation promoter is selected from Panax Ginseng Extract, Arctium Majus Extract nitric oxide, niacin,
caffeine, gingko biioba extract, bicyclic monoterpene diols, a-lipoic acid, ximenynic acid, proantnocyanidins, arginine and mixtures thereof,
Most preferably, the composition does not comprise Trichogen® ex Cognis, in particular Trichogen® Veg LS 8960.
Trichogen® Veg LS 8960. contains:
Panax Ginseng Root Extract, Arginine, Acetyl Tyrosine, Arctium Majus Root Extract, Hydroiysed Soy Protein, Zinc gluconate, Niacinamide, Biotin, Salvia Scfarea Extract, Cinnamomumb Zeyianrcurn Extract, Ginko Biioba Extract and Kigela Africana Extract.
The composition according to the invention may be in any product form, e.g. shampoo, mousse, conditioner, gel, mask and may be a rinse-off product or a leave-on product.
Depending on product form the composition according to the invention may aiso comprise any common ingredients typically found in such product form. For example, a shampoo will likely comprise cleansing surfactants; a conditioner will comprise conditioning agents selected from fatty alcohols, silicone and cationic surfactants, etc.
The invention will now be described with reference to the following embodiments.
EXAMPLE 1
The following are formulations according to embodiments of the invention.
Leave-on formulations
A B c D E F
Water and minors To 100% To 100% To 100% To 100% To 100% To 100%
Nafrosoi 250HHR 1.00 1.00 1.00 1.00 1.00 1.00
Glycerol 5.00 5.00 5.00 5.00 5.00 5.00
Zinc
gluconate 0.1 0.1 0.05 0.05 0.001 0.006
ClimbazoJe 0,02 0.001 0.02 0.001 0.008 0.06
Ethanol 1.0 1.0 1.0 1.0 1.0 1.0
Shamooo examples
Water and minors To 100% To 100% To 100% To 100%
Climbazole 0.5 0.5 0.5 0.5
Zinc gluconate 1.0 0.8 0.4 0.5
Texapon N70 7.70 7.70 7.70 7.70
Mackanate EL 12.50 12.50 12.50 12.50
Tegobetaine 9.60 9.60 9.60 9.60
Jaguar C13S 0.15 0.15 0.15 0.15
Jaguar C17 0.05 0.05 0.05 0.05
Sodium Hydroxide (50%) 0.05 0.05 0.05 0.05
Conditioners
Water To 100% To 100%
Lexamine S13 1.25 1.25
Ganamin BTLF 1.25 1.25
Laurex CS 5.00 5.00
Potassium Chloride 0.10 0.10
EDTA 0.10 0.10
Laurie Acid 0.30 0.30
Zinc gluconate 1.0 1.0
Climbazole 0.5 0.2
Propylene glycol 2.0 2.0
EXAMPLE 2
The following shows how zinc gluconate and climbazole provide an improved anti-trypsin effect.
1. Zinc Gluconate (0.00156%) plus climbazole
Ingredient Normalised activity
Control 1.0 1.0 1.0 1.0 1.0 1.0
(Trypsin only)
a. Climbazole 1.15
0.00391%
b. Climb 131
0.00781%
c. Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e, Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g. Zinc 1.03 1.03 1.03 1.03 1.03 1.03
gluconate
(0.00156%)
Calculated 1,045 0.969 1.165 1.22 1.17 1.09
efficacy
Experimental
efficacy 0.935 0.88 0.32 0.49 0.75 0.93
(synergy)
2, Zinc Gluconate (0.003125%) plus climbazole
Ingredient Normalised activity
Control 1.0 1.0 1.0 | 1.0 1.0 1,0
(Trypsin only)
a. Climbazole 1.15
0.00391%
b. Climb 1.31
0.00781%
c. Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e. Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g. Zinc 0.957 0.957 0.957 0.957 0.957 0.957
gluconate
(0.003125%)
Calculated 1.01 0.9325 1.1285 1.1835 1.1335 1.0535
efficacy
Experimental
efficacy 0.87 0.88 0.24 0.27 0.61 0.83
(synergy)
3. Zinc Gluconate (0,00625%) plus clirnbazole
Ingredient Normalised activity
Control 1.0 1.0 1.0 1.0 1.0 1.0
(Trypsin only)
a. Clirnbazole 1.15
0.00391 %
b, Climb 1.31
0.00781%
C Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e. Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g.Zinc 0.8404 0.8404 0.8404 0.8404 0.8404 0.8404
. gluconate
(0.00625%)
Calculated 0.95 0.874 1.07 1.125 1.075 0.995 ;
efficacy
Experimental
efficacy 0.753 1.10 0.328 0.037 0.384 0.578
(synergy)
CLAIMS
1. Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.
2. Hair treatment composition according to claim 1 wherein the azole fungicide is climabazole or ketoconazole.
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 2123-MUMNP-2011-FORM 3(10-12-2013).pdf | 2013-12-10 |
| 1 | 2123-MUMNP-2011-FORM-27 [27-09-2024(online)].pdf | 2024-09-27 |
| 2 | 2123-MUMNP-2011-FORM 3(10-11-2014).pdf | 2014-11-10 |
| 2 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)]-1.pdf | 2023-09-29 |
| 3 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)].pdf | 2023-09-29 |
| 3 | 2123-MUMNP-2011-FORM 3-(25-04-2015).pdf | 2015-04-25 |
| 4 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [27-09-2022(online)].pdf | 2022-09-27 |
| 4 | 2123-MUMNP-2011-CORRESPONDENCE(31-08-2015).pdf | 2015-08-31 |
| 5 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [09-09-2021(online)].pdf | 2021-09-09 |
| 5 | 2123-MUMNP-2011-CORRESPONDENCE(07-12-2015).pdf | 2015-12-07 |
| 6 | 2123-MUMNP-2011-FORM 3-(19-03-2016).pdf | 2016-03-19 |
| 6 | 2123-MUMNP-2011-CLAIMS(AMENDED)-(25-5-2015).pdf | 2018-08-10 |
| 7 | Petition Under Rule 137 [14-03-2017(online)].pdf | 2017-03-14 |
| 7 | 2123-MUMNP-2011-CLAIMS(AMENDED)-(28-5-2015).pdf | 2018-08-10 |
| 8 | Other Patent Document [15-03-2017(online)].pdf | 2017-03-15 |
| 8 | 2123-MUMNP-2011-CLAIMS(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 9 | 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(25-5-2015).pdf | 2018-08-10 |
| 9 | Form 26 [15-03-2017(online)].pdf | 2017-03-15 |
| 10 | 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(28-5-2015).pdf | 2018-08-10 |
| 10 | 2123-MUMNP-2011_EXAMREPORT.pdf | 2018-08-10 |
| 11 | 2123-MUMNP-2011-CLAIMS.pdf | 2018-08-10 |
| 11 | 2123-MUMNP-2011-WO INTERNATIONAL PUBLICATION REPORT A1.pdf | 2018-08-10 |
| 12 | 2123-MUMNP-2011-CORRESPONDENCE(12-1-2012).pdf | 2018-08-10 |
| 12 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-5-2015).pdf | 2018-08-10 |
| 13 | 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(29-3-2017).pdf | 2018-08-10 |
| 13 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(27-4-2015).pdf | 2018-08-10 |
| 14 | 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(FER)-(22-1-2015).pdf | 2018-08-10 |
| 14 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(25-5-2015).pdf | 2018-08-10 |
| 15 | 2123-MUMNP-2011-Correspondence-240715.pdf | 2018-08-10 |
| 15 | 2123-MUMNP-2011-OTHERS-240715.pdf | 2018-08-10 |
| 16 | 2123-MUMNP-2011-CORRESPONDENCE-251114.pdf | 2018-08-10 |
| 16 | 2123-MUMNP-2011-OTHERS(PROOF OF RIGHT)-25112014.pdf | 2018-08-10 |
| 17 | 2123-MUMNP-2011-OTHER PCT DOCUMENT.pdf | 2018-08-10 |
| 17 | 2123-MUMNP-2011-CORRESPONDENCE.pdf | 2018-08-10 |
| 18 | 2123-MUMNP-2011-DESCRIPTION(COMPLETE).pdf | 2018-08-10 |
| 18 | 2123-MUMNP-2011-OTHER DOCUMENT.pdf | 2018-08-10 |
| 19 | 2123-MUMNP-2011-DESCRIPTION(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 19 | 2123-MUMNP-2011-OTHER DOCUMENT(27-4-2015).pdf | 2018-08-10 |
| 20 | 2123-MUMNP-2011-FORM 1.pdf | 2018-08-10 |
| 20 | 2123-MUMNP-2011-Original Under Rule 6(1 A)Form 3-250117.pdf | 2018-08-10 |
| 21 | 2123-MUMNP-2011-FORM 18(12-1-2012).pdf | 2018-08-10 |
| 21 | 2123-MUMNP-2011-GENERAL POWER OF ATTORNEY(28-5-2015).pdf | 2018-08-10 |
| 22 | 2123-MUMNP-2011-FORM 2(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 23 | 2123-MUMNP-2011-FORM 2(TITLE PAGE)-(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 23 | 2123-MUMNP-2011-FORM PCT-IPEA-416.pdf | 2018-08-10 |
| 24 | 2123-MUMNP-2011-FORM PCT-IPEA-409.pdf | 2018-08-10 |
| 24 | 2123-MUMNP-2011-FORM 2(TITLE PAGE).pdf | 2018-08-10 |
| 25 | 2123-MUMNP-2011-FORM 5.pdf | 2018-08-10 |
| 25 | 2123-MUMNP-2011-FORM 2.pdf | 2018-08-10 |
| 26 | 2123-MUMNP-2011-FORM 3(15-2-2012).pdf | 2018-08-10 |
| 26 | 2123-MUMNP-2011-FORM 3.pdf | 2018-08-10 |
| 27 | 2123-MUMNP-2011-FORM 3(22-5-2014).pdf | 2018-08-10 |
| 27 | 2123-MUMNP-2011-Form 3-160816.pdf | 2018-08-10 |
| 28 | 2123-MUMNP-2011-FORM 3(22-6-2013).pdf | 2018-08-10 |
| 28 | 2123-MUMNP-2011-Form 3-081015.pdf | 2018-08-10 |
| 29 | 2123-MUMNP-2011-FORM 3(23-1-2013).pdf | 2018-08-10 |
| 29 | 2123-MUMNP-2011-FORM 3(8-8-2012).pdf | 2018-08-10 |
| 30 | 2123-MUMNP-2011-FORM 3(23-1-2013).pdf | 2018-08-10 |
| 30 | 2123-MUMNP-2011-FORM 3(8-8-2012).pdf | 2018-08-10 |
| 31 | 2123-MUMNP-2011-FORM 3(22-6-2013).pdf | 2018-08-10 |
| 31 | 2123-MUMNP-2011-Form 3-081015.pdf | 2018-08-10 |
| 32 | 2123-MUMNP-2011-FORM 3(22-5-2014).pdf | 2018-08-10 |
| 32 | 2123-MUMNP-2011-Form 3-160816.pdf | 2018-08-10 |
| 33 | 2123-MUMNP-2011-FORM 3(15-2-2012).pdf | 2018-08-10 |
| 33 | 2123-MUMNP-2011-FORM 3.pdf | 2018-08-10 |
| 34 | 2123-MUMNP-2011-FORM 2.pdf | 2018-08-10 |
| 34 | 2123-MUMNP-2011-FORM 5.pdf | 2018-08-10 |
| 35 | 2123-MUMNP-2011-FORM 2(TITLE PAGE).pdf | 2018-08-10 |
| 35 | 2123-MUMNP-2011-FORM PCT-IPEA-409.pdf | 2018-08-10 |
| 36 | 2123-MUMNP-2011-FORM PCT-IPEA-416.pdf | 2018-08-10 |
| 36 | 2123-MUMNP-2011-FORM 2(TITLE PAGE)-(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 37 | 2123-MUMNP-2011-FORM 2(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 38 | 2123-MUMNP-2011-FORM 18(12-1-2012).pdf | 2018-08-10 |
| 38 | 2123-MUMNP-2011-GENERAL POWER OF ATTORNEY(28-5-2015).pdf | 2018-08-10 |
| 39 | 2123-MUMNP-2011-FORM 1.pdf | 2018-08-10 |
| 39 | 2123-MUMNP-2011-Original Under Rule 6(1 A)Form 3-250117.pdf | 2018-08-10 |
| 40 | 2123-MUMNP-2011-DESCRIPTION(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 40 | 2123-MUMNP-2011-OTHER DOCUMENT(27-4-2015).pdf | 2018-08-10 |
| 41 | 2123-MUMNP-2011-DESCRIPTION(COMPLETE).pdf | 2018-08-10 |
| 41 | 2123-MUMNP-2011-OTHER DOCUMENT.pdf | 2018-08-10 |
| 42 | 2123-MUMNP-2011-CORRESPONDENCE.pdf | 2018-08-10 |
| 42 | 2123-MUMNP-2011-OTHER PCT DOCUMENT.pdf | 2018-08-10 |
| 43 | 2123-MUMNP-2011-CORRESPONDENCE-251114.pdf | 2018-08-10 |
| 43 | 2123-MUMNP-2011-OTHERS(PROOF OF RIGHT)-25112014.pdf | 2018-08-10 |
| 44 | 2123-MUMNP-2011-Correspondence-240715.pdf | 2018-08-10 |
| 44 | 2123-MUMNP-2011-OTHERS-240715.pdf | 2018-08-10 |
| 45 | 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(FER)-(22-1-2015).pdf | 2018-08-10 |
| 45 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(25-5-2015).pdf | 2018-08-10 |
| 46 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(27-4-2015).pdf | 2018-08-10 |
| 46 | 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(29-3-2017).pdf | 2018-08-10 |
| 47 | 2123-MUMNP-2011-CORRESPONDENCE(12-1-2012).pdf | 2018-08-10 |
| 47 | 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-5-2015).pdf | 2018-08-10 |
| 48 | 2123-MUMNP-2011-CLAIMS.pdf | 2018-08-10 |
| 48 | 2123-MUMNP-2011-WO INTERNATIONAL PUBLICATION REPORT A1.pdf | 2018-08-10 |
| 49 | 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(28-5-2015).pdf | 2018-08-10 |
| 49 | 2123-MUMNP-2011_EXAMREPORT.pdf | 2018-08-10 |
| 50 | 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(25-5-2015).pdf | 2018-08-10 |
| 50 | Form 26 [15-03-2017(online)].pdf | 2017-03-15 |
| 51 | 2123-MUMNP-2011-CLAIMS(GRANTED)-(29-3-2017).pdf | 2018-08-10 |
| 51 | Other Patent Document [15-03-2017(online)].pdf | 2017-03-15 |
| 52 | 2123-MUMNP-2011-CLAIMS(AMENDED)-(28-5-2015).pdf | 2018-08-10 |
| 52 | Petition Under Rule 137 [14-03-2017(online)].pdf | 2017-03-14 |
| 53 | 2123-MUMNP-2011-CLAIMS(AMENDED)-(25-5-2015).pdf | 2018-08-10 |
| 53 | 2123-MUMNP-2011-FORM 3-(19-03-2016).pdf | 2016-03-19 |
| 54 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [09-09-2021(online)].pdf | 2021-09-09 |
| 54 | 2123-MUMNP-2011-CORRESPONDENCE(07-12-2015).pdf | 2015-12-07 |
| 55 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [27-09-2022(online)].pdf | 2022-09-27 |
| 55 | 2123-MUMNP-2011-CORRESPONDENCE(31-08-2015).pdf | 2015-08-31 |
| 56 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)].pdf | 2023-09-29 |
| 56 | 2123-MUMNP-2011-FORM 3-(25-04-2015).pdf | 2015-04-25 |
| 57 | 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)]-1.pdf | 2023-09-29 |
| 57 | 2123-MUMNP-2011-FORM 3(10-11-2014).pdf | 2014-11-10 |
| 58 | 2123-MUMNP-2011-FORM 3(10-12-2013).pdf | 2013-12-10 |
| 58 | 2123-MUMNP-2011-FORM-27 [27-09-2024(online)].pdf | 2024-09-27 |